ADC- Anti Body Drug Conjugates (ADC) is an increasingly important pharmaceutical science that is good for independent consultants to know about. Chances are, you may do a project for an ADC company. From what LifeSciHub has heard, ADC companies strongly prefer independent consultants that have knowledge of or experience with ADC. Although this one single webinar, from an ADC vendor of some kind no less, is a far cry from a PhD in biochemistry, it could be a good introduction to the field. And independent consultants need free training resources when and however they can get them! If so motived, read on…
Antibody drug conjugates (ADCs) are attracting a tremendous amount of attention because they have the potential to revolutionise cancer treatment. Chemical ligation of cytotoxic agents to monoclonal antibodies allows the selective delivery of cytotoxins to tumour cells thereby potentially mitigating some of the damaging side-effects of cancer chemotherapy. There are currently nine FDA-approved ADCs and numerous others at varying stages of development. Concept Life Sciences has expertise in all aspects of ADC synthesis and characterisation allowing us to help expedite your ADC projects progression to the clinic.
At Concept Life Sciences, we are renowned for our synthetic organic chemistry expertise and have successfully delivered on numerous medicinal chemistry projects at varying stages of development. We have recently expanded our capabilities and expertise to offer tailored solutions to ADC projects. Our ADC portfolio includes linker synthesis, handling of potent cytotoxins, bioconjugation, aggregation analysis, drug-antibody ratio calculations via UV-visible absorption and mass spectrometry, peptide mapping and assessment of ADC potency against a range of target antigen expressing and non-expressing cell lines. We are also able to work with our partners to design and implement bespoke assays to ensure you get the data you need.
In this webinar we will give a brief overview of the current state of the ADC landscape and present the results of an internal project focussing on the non-proprietary ADC Trastuzumab-MC-Val-Cit-PAB-MMAE. In particular, we will highlight:
• ADC synthesis.
• ADC structural characterisation by subunit analysis and peptide mapping.
• The effect of antibodies and ADCs against target antigen-expressing and non-target antigen-expressing cell lines to study ADC specificity and their time dependent effect on apoptosis using an IncuCyte®.
• How the use of our sister company Malvern Panalytical’s state-of-the-art analytical instrumentation can be implemented in ADC research and development.
Concept Life Sciences has the knowledge, skills and capacity to be able to offer a range of solutions to help our clients expedite the progression of their ADC projects. The alliance with our sister company Malvern Panalytical allow us to support ADC projects with analytical expertise and advanced analytical instrumentation. Our team of experienced scientists, with depth and breadth of knowledge and expertise, share your passion for delivering science. Join us on Thursday 1st October to see how Concept Life Sciences can help expedite your ADC pipeline.
Principal Research Scientist
An organic chemist by training, Jamie received his PhD from University of Cambridge in 2014 for work on the development of small molecule strategies for targeting novel protein-protein interactions. Between 2014 and 2017 Jamie was a Roche Postdoctoral Research Fellow at Cambridge where he worked on a number of projects at the chemistry-biology interface including the design and synthesis of de-novo antibiotic-quorum sensing small molecule conjugates and the development of methodology to allow access to diverse collections of small molecule screening collections. Jamie has worked at Concept Life Sciences since 2017 on a number of different medicinal chemistry programs and has a special interest in new approaches to synthesis and antibody drug conjugates.
Darryl obtained his PhD from Napier University Edinburgh in association with Moredun Research Institute, in veterinary parasitology and immunology in 2008. Darryl continued post-doctoral research at Moredun Research Institute until 2012 when he moved to the University of Edinburgh to work for Steve Anderton on T cell biology in autoimmune diseases. In 2015 he transferred to Steve’s spin out company Aquila Biomedical which is now the Edinburgh site for Concept Life Sciences, where Darryl has been actively involved in developing new assays in various autoimmunity and immuno-oncology fields.
Key Learning Objectives
- To understand the capabilities and expertise that Concept Life Sciences has in the ADC field.
- To understand how the use of Malvern Panalytical’s instrumentation can be implemented in ADC research and development
- Senior Scientist
- Principal Scientist
- Lead Scientist
- Head of Research and Development
- VP Science
- VP Chemistry
- VP Biologics
- Head of Business Development
- Business Development Executive
- Proposals Manager
- VP of Business Development
- Chief Scientific Officer
- Head of Outsourcing
- Project Manager
- Product Manager
- Head of API
- Bioconjugation Scientist
- Group Leader
- Chief Executive Officer